Cyclo Therapeutics Stock Shares Owned By Insiders
CYTHW Stock | USD 0.13 0.01 7.14% |
Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.
Cyclo | Shares Owned By Insiders |
Cyclo Therapeutics Company Shares Owned By Insiders Analysis
Cyclo Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Cyclo Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Cyclo Therapeutics is extremely important. It helps to project a fair market value of Cyclo Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Cyclo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 0.0% of Cyclo Therapeutics are shares owned by insiders. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Cyclo Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Cyclo Fundamentals
Return On Equity | -226.64 | ||||
Return On Asset | -2.82 | ||||
Operating Margin | (45.78) % | ||||
Number Of Shares Shorted | 70 | ||||
Revenue | 1.08 M | ||||
EBITDA | (20.03 M) | ||||
Net Income | (20.06 M) | ||||
Cash And Equivalents | 2.24 M | ||||
Cash Per Share | 1.32 X | ||||
Total Debt | 1.03 M | ||||
Current Ratio | 0.87 X | ||||
Book Value Per Share | 0.17 X | ||||
Cash Flow From Operations | (16.19 M) | ||||
Beta | -0.38 | ||||
Market Capitalization | 62.76 M | ||||
Total Asset | 13.25 M | ||||
Retained Earnings | (83.86 M) | ||||
Working Capital | 3.85 M | ||||
Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.